SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-053303
Filing Date
2021-10-18
Accepted
2021-10-18 17:01:34
Documents
14
Period of Report
2021-10-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea149033-8k_protarathera.htm   iXBRL 8-K 40860
2 CONSULTING AGREEMENT, DATED AS OF OCTOBER 16, 2021, BY AND BETWEEN THE COMPANY ea149033ex10-1_protarathera.htm EX-10.1 59279
3 SEPARATION AGREEMENT AND RELEASE, DATED AS OF OCTOBER 15, 2021, BY AND BETWEEN T ea149033ex10-2_protarathera.htm EX-10.2 60801
  Complete submission text file 0001213900-21-053303.txt   368538

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE tara-20211015_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tara-20211015_pre.xml EX-101.PRE 22361
6 XBRL SCHEMA FILE tara-20211015.xsd EX-101.SCH 3028
7 EXTRACTED XBRL INSTANCE DOCUMENT ea149033-8k_protarathera_htm.xml XML 3669
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 211328793
SIC: 2836 Biological Products, (No Diagnostic Substances)